Caribou Biosciences (Caribou Biosciences) Change In Receivables : $1.23 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Caribou Biosciences Change In Receivables?

Caribou Biosciences's change in receivables for the quarter that ended in Mar. 2024 was $0.25 Mil. It means Caribou Biosciences's Accounts Receivable declined by $0.25 Mil from Dec. 2023 to Mar. 2024 .

Caribou Biosciences's change in receivables for the fiscal year that ended in Dec. 2023 was $0.81 Mil. It means Caribou Biosciences's Accounts Receivable declined by $0.81 Mil from Dec. 2022 to Dec. 2023 .

Caribou Biosciences's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.92 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Caribou Biosciences's Days Sales Outstanding for the three months ended in Mar. 2024 was 34.45.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Caribou Biosciences's liquidation value for the three months ended in Mar. 2024 was $231.14 Mil.

Caribou Biosciences Change In Receivables Historical Data

The historical data trend for Caribou Biosciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caribou Biosciences Change In Receivables Chart

Caribou Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-1.09

-1.18

-2.96

3.46

0.81

Caribou Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial													-0.18	1.10	-1.39	1.28	0.25

Caribou Biosciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.23 Mil.

Caribou Biosciences (NAS:CRBU) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Caribou Biosciences's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.917	/	2.429	*	91
=	34.45

2. In Ben Graham's calculation of liquidation value, Caribou Biosciences's accounts receivable are only considered to be worth 75% of book value:

Caribou Biosciences's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	293.988	-	63.536	+	0.75 * 0.917	+	0.5 * 0
=	231.14

Caribou Biosciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of Caribou Biosciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Caribou Biosciences (Caribou Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Caribou Biosciences Inc (NAS:CRBU) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

2929 7th Street, Suite 105, Berkeley, CA, USA, 94710

Website

https://www.cariboubio.com

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.

Executives

Syed Ali-aamir Rizvi	officer: Chief Medical Officer	C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Ryan Fischesser	officer: See Remarks	CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Steven Kanner	officer: See Remarks	CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
David Lee Johnson	director	C/O GLOBAL BLOOD THERAPEUTICS, 171 OYSTER POINT BLVD, STE. 300, SAN FRANCISCO CA 94080
Barbara G Mcclung	officer: See Remarks	CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Ruhi Ahmad Khan	officer: Chief Business Officer	C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Dara Richardson-heron	director	C/O CARIBOU BIOSCIENCES, INC., 29, BERKELEY CA 94710
Ran Zheng	director	2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Nancy Whiting	director	2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Fmr Llc	10 percent owner, other: See Remark 1	245 SUMMER STREET, BOSTON MA 02210
Natalie Sacks	director	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Scott Braunstein	director	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Rachel E. Haurwitz	director, officer: See Remarks	C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Andrew Guggenhime	director	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Jason O'byrne	officer: See Remarks	CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710